argenx (NASDAQ:ARGX) Given New $680.00 Price Target at Robert W. Baird

argenx (NASDAQ:ARGX - Free Report) had its price objective hoisted by Robert W. Baird from $650.00 to $680.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Other analysts have also recently issued research reports about the company. William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft downgraded argenx from a "hold" rating to a "sell" rating in a research note on Friday, January 17th. Evercore ISI boosted their price objective on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. Wedbush restated an "outperform" rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $662.83.

Remove Ads

argenx Stock Down 3.1 %

ARGX traded down $18.97 on Tuesday, reaching $594.21. The company's stock had a trading volume of 383,599 shares, compared to its average volume of 282,065. The company has a market capitalization of $36.10 billion, a price-to-earnings ratio of -675.24 and a beta of 0.58. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The stock has a 50 day moving average of $642.09 and a two-hundred day moving average of $593.03.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. As a group, analysts anticipate that argenx will post 3.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenx

Large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in argenx during the third quarter valued at about $88,339,000. Point72 Asset Management L.P. acquired a new stake in argenx during the fourth quarter worth about $91,013,000. Allspring Global Investments Holdings LLC raised its holdings in shares of argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after purchasing an additional 143,834 shares during the period. Finally, Marshall Wace LLP raised its holdings in shares of argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock worth $117,805,000 after purchasing an additional 124,271 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.